CBC device market seen reaching $5.76 billion by 2030

The complete blood count device market is projected to grow from $4.33 billion in 2025 to $5.76 billion by 2030, driven by rising blood disorder cases, more automated lab testing and faster diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Complete blood count devices support routine blood testing that helps clinicians diagnose and monitor a wide range of conditions. - Demand is rising as healthcare systems seek faster, more accurate blood analysis and more efficient laboratory workflows. - The market’s projected climb to $5.76 billion by 2030 signals steady demand for hematology diagnostics across hospitals, labs and point-of-care settings.

What happened: - The Business Research Company released a 2026 report on the global complete blood count device market. - The market is projected to increase from $4.33 billion in 2025 to $4.58 billion in 2026. - The report forecasts the market will reach $5.76 billion by 2030. - The report puts the market on a 5.9% CAGR path over the forecast period. - The report was published July 31, 2026. - Download a free sample of the report. - View the full market report.

The details: - CBC devices automate blood analysis by measuring blood components and their characteristics. - The devices help healthcare providers get accurate results faster for diagnosis and treatment decisions. - The market growth is being driven by higher volumes of clinical diagnostic testing. - More automation in hospital laboratories is adding demand for CBC devices. - A rising burden of chronic illness is also supporting growth. - Standardized blood testing protocols and routine health screenings are expanding use. - The report points to decentralized diagnostics, smart lab infrastructure, rapid result demands and preventive testing as additional growth factors. - Ongoing hematology technology innovation is another contributor. - The report highlights more automated hematology analyzers, greater use of point-of-care CBC devices, AI-powered diagnostics and high-throughput laboratory solutions as major trends. - The increasing prevalence of blood disorders is a core market driver. - Blood disorders can disrupt the production, function or structure of blood cells. - Lifestyle-related factors such as poor nutrition, low physical activity and stress are linked to conditions including anemia and clotting abnormalities. - CBC devices help identify those abnormalities and support earlier detection and treatment. - The Canadian Cancer Society reported in May 2024 that Canada recorded 4,100 new cases of multiple myeloma and 1,750 deaths from the disease.

Between the lines: - The market outlook reflects a broader shift toward decentralized and faster diagnostics, not just higher testing volume. - AI integration and automation point to a push for more precise and scalable lab operations. - The blood disorder data cited in the report reinforces why hematology testing remains a recurring need rather than a one-time equipment cycle. - North America led the market in 2025 because of advanced healthcare infrastructure and high adoption of diagnostic technologies. - Asia-Pacific is expected to grow fastest through 2030 as healthcare access expands, governments increase support and awareness of blood health rises.

What's next: - Wider adoption of automated analyzers and point-of-care devices is likely to shape purchasing decisions through 2030. - Growth in preventive care and rapid testing should keep pressure on labs to upgrade hematology systems. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - CBC devices are moving from a steady diagnostic category to a growth market shaped by automation, decentralized testing and rising blood disorder detection.